Nocturia Market Research Explores Growth Within A $4.5 Billion Opportunity

The nocturia market is on track for significant expansion in the coming years, driven by various healthcare advancements and shifting patient needs. Understanding the current market size, key players, and emerging trends offers valuable insight into this specialized sector's future trajectory.

Forecasted Market Value and Growth of the Nocturia Market
The nocturia industry is projected to reach a market size of $4.51 billion by 2030, growing steadily at a compound annual growth rate (CAGR) of 7.7%. This upward trend is fueled by several factors, including an increasing demand for personalized treatment options, the rise of home care therapies, higher healthcare spending, and a growing focus on managing sleep quality. Additionally, broader access to urology specialists supports this market growth. Significant trends expected to influence the market over the forecast period include the aging population and related urological conditions, increasing cases of diabetes and metabolic disorders, greater awareness and diagnosis of lower urinary tract symptoms, a shift toward combination drug therapies, and the expansion of home-based nocturia care.

The nocturia market size has grown strongly in recent years. It will grow from $3.1 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to aging population growth, increased incidence of benign prostatic hyperplasia, rising prevalence of urinary tract infections, widespread use of diuretic medications, limited early diagnostic awareness.

Download a free sample of the nocturia market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21232&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving the Nocturia Market Forward
Several prominent pharmaceutical firms dominate the nocturia industry, including Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, and Wellesley Pharmaceuticals Inc.

Strategic Collaborations Expanding Market Reach
In March 2023, KYORIN Pharmaceutical Co., Ltd., a Japan-based company, formed a licensing agreement with Sumitomo Pharma to commercialize vibegron, a therapy for overactive bladder, across Taiwan, Hong Kong, Singapore, Indonesia, and Vietnam. This partnership aims to leverage Sumitomo Pharma's capabilities in development, manufacturing, and commercialization to boost the drug's presence in these rapidly growing Asian markets. Sumitomo Pharma focuses strategically on developing treatments addressing unmet medical needs, making this collaboration well-aligned with its business goals.

View the full nocturia market report:
https://www.thebusinessresearchcompany.com/report/nocturia-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Product Developments in the Nocturia Market
Pharmaceutical companies in the nocturia field are increasingly prioritizing the development of advanced formulations to improve patient adherence and convenience. One notable innovation is orally disintegrating tablets (ODTs), which dissolve quickly in the mouth without requiring water - a major benefit for patients who have difficulty swallowing traditional pills. For example, in July 2024, Malta-based Adalvo Limited introduced Desmopressin ODT in Europe, targeting conditions that lead to excessive fluid loss such as central cranial diabetes insipidus. This synthetic vasopressin formulation helps regulate urine output and is also used to manage bleeding in mild to moderate hemophilia A and von Willebrand disease by stimulating clotting factor release.

Segment Analysis and Market Outlook for the Global Nocturia Industry
The nocturia market is divided into multiple segments to better understand its composition and growth drivers:
1) Drug Type: Includes Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodics, and Other Drugs.
2) Indications: Covers Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, and Global Polyuria.
3) Causes: Categorized by Urological Infection, Bladder Tumors, Diuretic Medication use, Regular Alcohol or Coffee consumption, Liver Infection, Diabetes, Pregnancy, and Other Causes.
4) End Users: Consist of Hospitals, Home Care, and Clinics.

Further breakdown of drug categories includes:
- Anticholinergic Drugs such as Oxybutynin, Tolterodine, Solifenacin, Darifenacin, and Fesoterodine.
- Desmopressin available in Intranasal and Oral forms.
- Antibiotics including Nitrofurantoin, Trimethoprim, and Fosfomycin.
- Antispasmodics such as Hyoscine Butylbromide and Flavoxate.
- Other drugs like Alpha-Blockers and Beta-3 Agonists.

This detailed segmentation provides a comprehensive view of the market's structure and helps pinpoint areas of growth and innovation for stakeholders and investors alike.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.